ArticleBMC research notes2025
Molecular identification and antifungal susceptibility profile of rare and emerging yeast species causing onychomycosis.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Oral Cryptococcosis due to Naganishia diffluens in a Patient With Thalassemia: A Case Report and a Literature Review.Journal of clinical laboratory analysis · 2026Review
- Urinary tract infection caused by rare yeastFrontiers in immunology · 2026Review
- Fingernail Onychomycosis: A Laboratory-Based Retrospective Study with Species Profiling and Antifungal Susceptibility of Yeasts.Journal of clinical medicine · 2026Article
- Antifungal Susceptibilities of Rare Yeast Isolates.Journal of fungi (Basel, Switzerland) · 2025Article
- Onychomycosis in Diabetics: A Common Infection with Potentially Serious Complications.Life (Basel, Switzerland) · 2025Review
- Not all "Candida" are "Candida": Nakaseomyces glabratus (H.W. Anderson) Sugita & M. Takask. 2022 onychomycosis and the need for rapid diagnostic.FEMS microbiology letters · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOnychomycosis is a nail infection caused by various fungal agents. In recent years, there has been an increase in cases of onychomycosis caused by rare fungi, which are often challenging to identify using conventional methods. Sometimes, these unusual species exhibit different antifungal susceptibility patterns compared to more common yeast species. Therefore, this study aimed to identify rare yeast species causing onychomycosis and assess their antifungal susceptibility profiles.
resultsNineteen rare and emerging yeast isolates, representing seven species, including Candida orthopsilosis (n = 9, 47.36%), Clavispora lusitaniae (formerly Candida lusitaniae) (n = 2, 10.52%), Wickerhamiella pararugosa (formerly Candida pararugosa) (n = 2, 10.52%), Naganishia diffluens (formerly Cryptococcus diffluens) (n = 2, 10.52%), Wickerhamomyces anomalus (n = 2, 10.52%), Cyberlindnera fabianii (n = 1, 5.26%), and Meyerozyma caribbica (formerly Candida fermentati) (n = 1, 5.26%), were identified. Most rare yeast agents exhibited high minimum inhibitory concentration (MIC) values for fluconazole.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.